<DOC>
	<DOCNO>NCT01636401</DOCNO>
	<brief_summary>The purpose study observe Efficacy safety 400 μg twice daily aclidinium bromide vs. placebo administer patient moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Efficacy Safety 400 μg Twice Daily Aclidinium Bromide v . Placebo When Administered Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>A diagnosis stable moderate severe COPD define GOLD ( Global Initiative Chronic Obstructive Lung Disease ) guideline ( http : //www.goldcopd.org ) ; postbronchodilator FEV1/forced vital capacity [ FVC ] ratio &lt; 70 % FEV1 ≥ 30 % &lt; 80 % predict value . Current former cigarette smoker smoke history least 10 packyears . History current diagnosis asthma Patients hospitalize acute COPD exacerbation within 3 month prior Visit 1 Any respiratory tract infection ( include upper respiratory tract ) COPD exacerbation 6 week Visit 1 . Patients clinically significant respiratory condition COPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>